To include your compound in the COVID-19 Resource Center, submit it here.

FDA flags deaths, dosing ahead of sirukumab panel

In briefing documents released ahead of a planned advisory committee meeting, FDA reviewers raised concerns about a trend towards increased mortality seen with rheumatoid arthritis candidate sirukumab (CNTO 136) compared to placebo.

FDA's Arthritis Advisory Committee (AAC) is

Read the full 371 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE